Mechanistic Investigation of Chronic Neuropathologic Interaction Between Viral Infection and Progression of Lewy Pathology and Dementia
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R01NS148641-01
Grant search
Key facts
Disease
COVID-19Start & end year
20262030Known Financial Commitments (USD)
$582,172Funder
National Institutes of Health (NIH)Principal Investigator
ASSOCIATE PROFESSOR Xiaohong LuResearch Location
United States of AmericaLead Research Institution
LOUISIANA STATE UNIV HSC SHREVEPORTResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Post acute and long term health consequences
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Project Summary/Abstract Neuropathological interactions between COVID-19 and ADRD suggest shared molecular and cellular mechanisms. A recent case series study revealed striking cutaneous Lewy pathology (phosphorylated α- synuclein) in Long-COVID Postural orthostatic tachycardia syndrome (POTS) patients. Animal studies consistently show that viral infection can trigger α-synucleinopathies in hamster and macaque SARS-CoV-2 infection models. SARS-CoV-2 N-and Spike protein can bind to α-Synuclein to induce Lewy pathology in vitro. Recent human single-neuron sequencing findings of accumulation of non-germline inherited somatic mutations associated with neurodegenerative disorders support the pathogenic role of genotoxic stress in age-dependent long-lasting neurologic deficits and cognitive decline. These observations support the role of infection in the pathogenesis of synucleinopathy, a pathological intracellular proteinaceous α-Synuclein (α-Syn) inclusions that are characteristic of neurological disorders, including dementia with Lewy body (DLB), with DLB being the second most common type of dementia after AD. Ours and other studies have begun to reveal the role of genotoxic stress interplaying with autophagy-lysosome function in synucleinopathy. To study the impact of virus infection on synucleinopathy in vivo, we generated a human ACE2 transgenic mouse model with full-length human ACE2 regulatory regions that faithfully recapitulated the structure, tissue distribution, and gene regulation of the human gene. SARS-CoV-2 infection in ABSL-3 facility established the feasibility of our model to study post-acute sequelae of COVID-19 (PASC) and age-dependent progression of neuropathology without viral neuroinvasion and lethal encephalitis, providing distinct advantages over the existing animal models. Compelling vivo data indicates that inhibiting genotoxic stress can effectively lessen inflammation, cell senescence, accumulation of α-Synuclein, autophagy deficits, neuroinflammation, and cognitive and anosmia symptoms in an immunopathology model without viral neural invasion. ATM inhibition only in genotoxic stressed cells via a novel genetic strategy also rescued α-Synuclein aggregates spreading and cognitive deficits, suggesting a causal pathogenic role of genotoxic stress in synucleinopathy and long COVID symptoms. We hypothesize viral infection-driven brain genotoxic stress mediates the pathologic interaction between COVID-19 and DLB via perpetuating DDR/cell senescence, autophagy/lysosome acidification dysfunction, and neuroinflammation that sustains chronic cognitive and neurological deficits. To test the hypothesis, Aims 1 and 2 will determine how viral infection as an etiologic factor can drive chronic olfactory and cognitive deficits, as well as Lewy pathology, with genotoxic stress as a prominent feature and key initiating factor. Aim 3 will establish the causal role of brain genotoxic stress and pathogenic mechanisms in PASCs, Lewy pathology, and dementia. The findings will transform the current paradigm of the viral origin of neurodegeneration and advance the therapeutic targeting of genotoxic stress for PASCs, Lewy pathology, and dementia.